Immunosuppressants Global Market Report 2024

Immunosuppressants are medications used to prevent the immune system from attacking healthy cells, primarily to prevent transplant rejection and manage autoimmune diseases. Careful monitoring is necessary due to their potency and potential side effects.

Key classes of drugs in this market include corticosteroids, monoclonal antibodies (MABs), calcineurin inhibitors, mTOR inhibitors, anti-proliferative agents, among others. Monoclonal antibodies are produced by cloning a single white blood cell and are traceable back to that parent cell. These medications are indicated for organ transplantation, autoimmune disorders, and non-autoimmune inflammatory diseases. They are distributed through hospital pharmacies, retail pharmacies, and online channels.

The immunosuppressants market research report is one of a series of new reports from The Business Research Company that provides immunosuppressants market statistics, including the immunosuppressants industry's global market size, regional shares, competitors with an immunosuppressants market share, detailed immunosuppressants market segments, market trends and opportunities, and any further data you may need to thrive in the immunosuppressants industry. This immunosuppressants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The immunosuppressants market size has grown rapidly in recent years. It will grow from $25.94 billion in 2023 to $29.72 billion in 2024 at a compound annual growth rate (CAGR) of 14.6%. The growth observed in the historic period can be attributed to advancements in transplant medicine, continuous drug development and innovation, regulatory approvals, an increase in transplant surgeries, and the emphasis on clinical efficacy and safety measures.

The immunosuppressants market size is expected to see rapid growth in the next few years. It will grow to $48.88 billion in 2028 at a compound annual growth rate (CAGR) of 13.2%. Forecasted growth relies on targeted therapies, precision medicine, biologics and biosimilars progress, immunotherapy combinations, gene therapy, and innovative drug delivery. Anticipated trends include expanded therapy indications, heightened focus on regulatory and safety concerns, precision medicine adoption, telehealth utilization, and biosimilars/generics prominence.

The growth of the immunosuppressant market is primarily attributed to the increasing prevalence of organ transplant procedures, particularly kidney and liver transplants, driven by the rising incidences of organ failure. Notably, the American Kidney Fund reported in June 2022 that the national transplant waiting list in the US would exceed 106,000 individuals, with 87% of them awaiting kidney transplants. This surge in organ transplantation cases is expected to be a key driver for the growth of the immunosuppressant market.

The immunosuppressant market is poised for growth due to the escalating instances of autoimmune diseases. Autoimmune diseases, characterized by abnormal immune responses attacking healthy cells, tissues, and organs, are on the rise. Immunosuppressant medications prove beneficial in managing autoimmune conditions such as rheumatoid arthritis, offering relief from symptoms and slowing down disease progression. A significant example is the data from the Centers for Disease Control and Prevention in June 2023, indicating that 54.4 million adults in the US were diagnosed with arthritis, a figure expected to reach 78 million by 2040. Moreover, the United Nations' World Population Prospect data in November 2022 projected a rise in the share of the global population aged 65 and above from 10% in 2022 to 16% in 2050. This increasing prevalence of autoimmune diseases, particularly in the aging population, is anticipated to drive the demand for immunosuppressants in the market.

The anticipated hindrance to the growth of the immunosuppressants market stems from stringent government regulations imposed during the drug approval process by regulatory bodies such as the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA). These regulatory authorities, committed to ensuring public safety, subject immunosuppressant drugs to rigorous evaluation regarding their safety and efficacy for patients with defined clinical conditions. Sponsors seeking approval must provide satisfactory evidence, and any immunotoxicology evaluation information becomes subject to review by the Center for Drug Evaluation and Research (CDER). The European Union (EU) has also adopted various guidelines, encompassing general, quality, and non-clinical and clinical aspects. Consequently, the stringent regulatory and approval procedures pose challenges to the overall growth of the immunosuppressants market.

The emergence of Phenotypic Personalized Medicine (PPM), employing a hybrid of artificial intelligence and physician intervention, presents a novel approach. Tacrolimus, a widely used immunosuppressant for organ transplant patients, requires frequent monitoring and adjustments during hospitalization. The PPM approach utilizes a computational platform, considering factors such as the patient's historical drug response, concurrent medications, and current liver and kidney data. This approach empowers physicians to identify optimal drug and dose combinations from a range of possibilities, enhancing personalization and effectiveness in drug dosing. Artificial intelligence, through PPM, not only facilitates more personalized drug dosing but also enriches physicians' decision-making capabilities by providing clinical data rather than predicted responses.

Major companies operating in the immunosuppressant market are focusing on developing innovative drugs such as prograf to prevent organ rejection in adult and pediatric patients receiving lung transplantation. Prograf is a calcineurin inhibitor, which is a type of immunosuppressant drug. It works by blocking the calcineurin pathway, which is involved in the immune response. This helps to suppress the immune system and prevent the body from rejecting the transplanted organ or treating eczema as a threat. For instance, in July 2021, Astellas Pharma Inc., a Japan-based pharma company, received approval for Prograf (tacrolimus) from the U.S. Food and Drug Administration (FDA) for use in combination with other immunosuppressant drugs to prevent organ rejection in adult and pediatric patients receiving lung transplantation. Prograf marks the first approval of an immunosuppressant drug to prevent rejection in adults and pediatric patients receiving lung transplants, making it the only approved immunosuppressant drug product on the market.

Prominent companies in the immunosuppressant market are directing their efforts towards the development of innovative drugs, exemplified by Prograf, designed to prevent organ rejection in both adult and pediatric patients undergoing lung transplantation. Prograf, classified as a calcineurin inhibitor, operates as a type of immunosuppressant drug. Its mechanism involves blocking the calcineurin pathway, a crucial component in the immune response, leading to immune system suppression. This action is instrumental in averting the rejection of transplanted organs and treating conditions such as eczema perceived as a threat by the immune system. A notable example is Astellas Pharma Inc., a Japan-based pharmaceutical company, which achieved approval for Prograf (tacrolimus) from the U.S. Food and Drug Administration (FDA) in July 2021. The approval pertained to Prograf's use in combination with other immunosuppressant drugs for preventing organ rejection in both adult and pediatric patients undergoing lung transplantation. This marked a significant milestone as Prograf became the first immunosuppressant drug approved for preventing rejection in adults and pediatric patients undergoing lung transplants. Consequently, Prograf stands as the sole approved immunosuppressant drug product in the market, reflecting the pioneering efforts of major companies in advancing therapeutic solutions in the field.

In October 2022, Amgen Inc., a U.S.-based biopharmaceutical and biotechnology company, successfully acquired ChemoCentryx Inc. for $3.7 billion. This strategic acquisition significantly augments Amgen's portfolio of drugs focused on inflammation and nephrology. Additionally, the acquisition brings three therapeutic candidates in the early stages that target chemoattractant receptors, address additional inflammatory conditions, and explore an oral cancer checkpoint. ChemoCentryx, Inc., the acquired company, is a U.S.-based biopharmaceutical firm specializing in the development and commercialization of novel drugs for cancer, autoimmune disorders, and inflammatory illnesses.

Major companies operating in the immunosuppressants market report are Pfizer Inc.; Johnson & Johnson Services Inc.; BASF SE; F Hoffmann La Roche Ltd.; AbbVie Inc.; Allergan plc; Novartis AG; Sanofi SA; Bristol-Myers Squibb Co.; GlaxoSmithKline plc; Covestro AG; Mylan Laboratories Inc.; Teva Pharmaceuticals USA Inc.; Astellas Pharma Inc.; Sandoz Inc.; Aurobindo Pharma Limited; Hikma Pharmaceuticals plc; Intas Pharmaceuticals Ltd.; Zydus Lifesciences Limited; Glenmark Pharmaceuticals Ltd.; Fresenius Kabi USA; Lupin Pharmaceuticals Inc.; Strides Pharma Inc.; Accord Healthcare Ltd.; RPG Life Sciences Limited; Genzyme Transgenics Corp.; Akriti Pharmaceuticals Pvt. Ltd.; SEBELA PHARMACEUTICALS Inc.; Healthy Life Pharma Private Limited; Apotex Inc.

North America was the largest region in the immunosuppressants market in 2023. The regions covered in the immunosuppressants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the immunosuppressants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The immunosuppressants market consists of sales of induction drugs, maintenance drugs, corticosteroids, and calcineurin inhibitors. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Immunosuppressants Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on immunosuppressants market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for immunosuppressants ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The immunosuppressants market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Drug Class: Corticosteroids; Monoclonal Antibodies (mAbs); Calcineurin Inhibitors; mTOR Inhibitors; Anti-Proliferative Agents; Other Drug Classes
• 2) By Indication: Organ Transplantation; Autoimmune Disorders; Non-Autoimmune Inflammatory Diseases
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; BASF SE; F Hoffmann La Roche Ltd.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.